Verastem, Inc. (VSTM) Stock Analysis
A live, multi-source view of Verastem, Inc. (VSTM): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd.
Sector: Healthcare · Industry: Biotechnology · United States · 102 employees · verastem.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Verastem, Inc. (VSTM) had a market capitalization of $742.6M (forward -10.9) and a beta of 0.32; the shares traded in a 52-week range of $3.43 – $10.82 (-19.8% over the year).
- Market cap
- $742.6M
- Enterprise value
- $690.6M
- Forward P/E
- -10.9
- Price / book
- 14.86
- EPS (trailing)
- $-2.44
- EPS (forward)
- $-0.75
- Payout ratio
- 0.0%
- 52-week range
- $3.43 – $10.82
- 52-week change
- -19.8%
- Beta
- 0.32
- Average volume
- 2.4M
- Shares outstanding
- 90.6M
- Short % of float
- 21.00%
- Profit margin
- -231.6%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-09
In RapidTradeView’s 2026-09-09 scan of the US universe, Verastem, Inc. (VSTM) last closed at $8.08 (the last completed close before that scan).
Technicals at the scan: RSI 70 (neutral territory), price +10.7% versus its 20-day average, 20-day versus 50-day average spread +16.6%, MACD histogram 0.05.
Sentiment inputs: 75% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 78/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of VSTM; corporate insiders filed 0 buys and 1 sell (1 filer, latest disclosure 2026-08-05). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Dan Paterson (0B/1S). Who is trading what
RapidTradeView pick record
VSTM has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Verastem, Inc. (VSTM) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell VSTM.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.